Clinical Trials
Multiple Phase IV clinical trials conducted by the Bandim Health Project evaluate health outcomes associated with DTP3 administration, focusing on adverse events, infant morbidity and mortality, hospitalization, and non-specific effects of vaccines such as BCG. A completed study investigated overall mortality, child survival, and hospitalization rates following vaccination protocols. Additionally, a trial currently enrolling by invitation assesses female infant survival and morbidity following BCG revaccination in conjunction with DTP3.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07005726 | ENROLLING_BY_INVITATION | Infant Morbidity; Infant Mortality; Non-Specific Effects of Vaccines; BCG |
Bandim Health Project |
2025-05-09 | PHASE4 |
| NCT00244673 | COMPLETED | Mortality; Hospitalization; Adverse Events |
Bandim Health Project |
2005-10 | PHASE4 |
(data from https://clinicaltrials.gov, updated on 2025-06-12)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).